Kinarus

Kinarus is a clinical-stage pharmaceutical company focused on providing new therapeutic options for patients with viral, respiratory, and ophthalmic diseases. The company’s lead candidate, KIN001, combines a clinical-stage p38 mitogen-activated protein kinase (p38 MAPK) inhibitor licensed from Roche with an already marketed drug to offer an oral, long-term effective treatment for patients suffering from conditions that significantly impact quality of life.